Identification of adipose tissue‐derived exosomal microRNA as a novel causal biomarker for cognitive impairment in type 2 diabetes mellitus: Triangulating evidence from Mendelian randomization and multicentre population studies
Aims To explore serum exosomal microRNAs (miRNAs) as risk biomarkers for early detection of cognitive impairment in type 2 diabetes mellitus (T2DM) patients. Materials and Methods This study included two phases: a discovery phase and a validation phase. To detect adipose tissue exosomal biomarkers f...
Saved in:
Published in | Diabetes, obesity & metabolism Vol. 27; no. 3; pp. 1265 - 1275 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.03.2025
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1462-8902 1463-1326 1463-1326 |
DOI | 10.1111/dom.16121 |
Cover
Loading…
Summary: | Aims
To explore serum exosomal microRNAs (miRNAs) as risk biomarkers for early detection of cognitive impairment in type 2 diabetes mellitus (T2DM) patients.
Materials and Methods
This study included two phases: a discovery phase and a validation phase. To detect adipose tissue exosomal biomarkers for T2DM patients, small RNA sequencing was conducted on a discovery population consisting of six T2DM patients and five subjects with normal glucose tolerance. To identify miRNAs with causal effects on cognitive impairment, Mendelian randomization (MR) analysis using publicly available genome wide association studies (GWAS) datasets was performed. Relationships between serum exosomal miRNAs and cognitive impairment were evaluated in a training population of 207 T2DM patients, and further validated in an external population of 101 T2DM patients from multiple centres.
Results
In the discovery phase, 13 exosomal miRNAs were significantly upregulated in adipose tissue of T2DM patients. MR analyses identified that increased miR‐125a‐5p was causally associated with increased Alzheimer's disease (AD) risk (OR = 1.231, 95% CI 1.062–1.426). In the validation phase, higher serum exosomal miR‐125a‐5p levels were related to increased amnestic mild cognitive impairment (aMCI) risk (OR = 1.066, 95% CI 1.030–1.103) and reduced left hippocampal body volume (r = −0.189, p < 0.05), achieving an area under the curve (AUC) of 0.728 for identifying aMCI in T2DM patients. External validation confirmed a diagnostic AUC of 0.738.
Conclusions
Serum exosomal miR‐125a‐5p derived from adipose tissue can serve as a causal biomarker for cognitive impairment in T2DM patients. |
---|---|
Bibliography: | Sijue Yang, Yue Yuan and Bing Zhang contributed equally to this work. Prior Presentation: This study has been accepted as an oral abstract presentation (#2024‐A‐3267‐Diabetes) at the American Diabetes Association's 84th Scientific Sessions, 21–24 June 2024 in Orlando, Florida. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 1462-8902 1463-1326 1463-1326 |
DOI: | 10.1111/dom.16121 |